Jason Mills

Mr. Mills has been a publishing sell-side analyst with coverage of medical devices for over 15 years. His areas of coverage include Cardiovascular, Imaging/Robotics, Ophthalmology and Women's Healthcare. Mr. Mills joined Canaccord Genuity from First Albany Capital where he was managing director and senior medical devices analyst, and he previously served as a vice president and senior med-tech analyst with Thomas Weisel Partners (now part of Stifel), Mr. Mills has earned awards for his stock picking, including the #2 ranked Medical Devices analyst in the The Wall Street Journal's 2011 "Best on the Street" Survey and #1 in the Medical Products segment of Forbes 2010 Best Brokerage Analysts. Mr. Mills holds a BA in Economics from Yale University and Master of Sports Administration from Ohio University.
Recent Quotes
"We believe EW is best positioned in TAVR among the current Big 2."
—
Jason Mills, Canaccord Genuity
(2/13/13)
more >
"EW's SAPIEN performed better with regard to PVL versus CoreValve."
—
Jason Mills, Canaccord Genuity
(9/4/12)
more >
"We reiterate our Buy rating for EW and are increasing our target price."
—
Jason Mills, Canaccord Genuity
(6/24/12)
more >
"We think this is a fantastic start to EW's U.S. TAVI launch."
—
Jason Mills, Canaccord Genuity
(5/1/12)
more >
"We're looking for EW's transcatheter valve franchise to grow 40–50% over the next two years."
—
The Life Sciences Report Interview with Jason Mills
(4/18/12)
more >
"ISRG remains one of the best, most consistent growth companies in medtech."
—
Jason Mills, Canaccord Genuity
(4/16/12)
more >
"We believe results will support FDA approval of EW's SAPIEN."
—
Jason Mills, Canaccord Genuity
(3/26/12)
more >